IL131386A0 - Method for the detection and localization of malignant human tumours - Google Patents

Method for the detection and localization of malignant human tumours

Info

Publication number
IL131386A0
IL131386A0 IL13138698A IL13138698A IL131386A0 IL 131386 A0 IL131386 A0 IL 131386A0 IL 13138698 A IL13138698 A IL 13138698A IL 13138698 A IL13138698 A IL 13138698A IL 131386 A0 IL131386 A0 IL 131386A0
Authority
IL
Israel
Prior art keywords
detection
composition
relates
neurotensin
malignant tumors
Prior art date
Application number
IL13138698A
Other languages
English (en)
Original Assignee
Mallinckrodt Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Medical Inc filed Critical Mallinckrodt Medical Inc
Publication of IL131386A0 publication Critical patent/IL131386A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/085—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being neurotensin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)
  • Nuclear Medicine (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • External Artificial Organs (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL13138698A 1997-02-03 1998-02-02 Method for the detection and localization of malignant human tumours IL131386A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97200297 1997-02-03
PCT/US1998/001964 WO1998033531A1 (en) 1997-02-03 1998-02-02 Method for the detection and localization of malignant human tumours

Publications (1)

Publication Number Publication Date
IL131386A0 true IL131386A0 (en) 2001-01-28

Family

ID=26146106

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13138698A IL131386A0 (en) 1997-02-03 1998-02-02 Method for the detection and localization of malignant human tumours

Country Status (11)

Country Link
US (2) US6312661B1 (no)
EP (1) EP0968001B1 (no)
JP (1) JP2001511152A (no)
AT (1) ATE253381T1 (no)
AU (1) AU728712C (no)
CA (1) CA2279530C (no)
DE (1) DE69819478T2 (no)
HU (1) HUP0001316A3 (no)
IL (1) IL131386A0 (no)
NO (1) NO993846L (no)
WO (1) WO1998033531A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3340699B2 (ja) * 1998-06-05 2002-11-05 東京瓦斯株式会社 膵外分泌機能診断剤
US7232559B1 (en) 1999-06-04 2007-06-19 Tokyo Gas Company Limited Diagnostic agents for pancreatic exocrine function
WO2001030398A2 (en) * 1999-10-22 2001-05-03 Insight Neuroimaging Systems, Llc Ligand chelated paramagnetic mri contrast agents
US8175890B2 (en) * 2001-10-30 2012-05-08 Biodose, Llc Pharmacy based method and algorithm for handling of radioactive pharmaceuticals and generating of reports therefrom
US7630907B2 (en) * 2001-10-30 2009-12-08 Biodose, Llc Algorithm and program for the handling and administration of radioactive pharmaceuticals
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
EP1587944A4 (en) 2002-03-01 2007-03-21 Dyax Corp KDR AND VEGF / KDR BINDING PEPTIDES AND THEIR USE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US20040039241A1 (en) * 2002-05-29 2004-02-26 Biodose Llc Integrated distribution and communication process and algorithm for providing, handling, distributing or generating reports regarding radioactive pharmaceuticals
WO2004009614A2 (en) * 2002-07-24 2004-01-29 The Salk Institute For Biological Studies Receptor (sstr4)- selective somatostatin analogs
GR1004637B (el) * 2003-04-04 2004-07-23 Βιομεντικααλαιφασαιενσισαανωνυμηαεταιριααφαρμακευτικωναπροιοντωναα Συνθεσηαβιολογικηακαιαπροκλινικηααξιολογησηααναλογωνανευροτενσινησα}@@bατροποποιημενωναμεαπαραγωγαατουᐏ@ϊ@τετρααζαενδεκανιουα}@ϊ@tetraazaundecanebακαιαεπισημασμενωναμεατεχνητιο@mα}αηαλλααραδιονουκλιδιαατουατεχνητιουbαη@καιαρηνιο@ϊϊα}΄ηααλλααραδιονουκλιδιαατουαρηνιουbαγιααεφαρμογηαστηναογκολογιαα
BRPI0414512B8 (pt) * 2003-09-17 2021-05-25 Board Of Regentes The Univ Of Texas System composição para reproduzir imagens de um pâncreas e uso desta
US20060062729A1 (en) * 2004-09-09 2006-03-23 Carraway Robert E Enhanced ligand binding to neurotensin receptors
US7507547B2 (en) * 2004-09-09 2009-03-24 University Of Massachusetts Screening assays for antioxidants and antiproliferative compounds
EP2374003B1 (en) 2009-01-07 2015-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment, the prognostic assessment and the detection of breast cancer
WO2011006985A1 (en) * 2009-07-16 2011-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors
US8378134B2 (en) 2009-09-30 2013-02-19 General Electric Company Hydroxylated contrast enhancement agents
EP2740726A1 (en) 2012-12-07 2014-06-11 3B Pharmaceuticals GmbH Neurotensin receptor ligands
EP2954933A1 (en) 2014-06-10 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand
EP2954934A1 (en) 2014-06-11 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand and use thereof
EP3154638A1 (en) 2014-06-10 2017-04-19 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687680A1 (fr) * 1992-02-20 1993-08-27 Centre Nat Rech Scient Procede de marquage de proteines et de peptides par acylation de leur fonction alpha aminee par un reactif comportant une fonction carboxylique activee.
EP0636032A1 (en) * 1992-03-25 1995-02-01 Mallinckrodt Medical, Inc. Method of intraoperatively detecting and locating tumoral tissues
CA2086453A1 (en) * 1992-12-30 1994-07-01 Mcgill University Marker for neurotensin receptor
DE4337599A1 (de) * 1993-11-01 1995-05-04 Diagnostikforschung Inst Metallbindende cysteinfreie Peptide für Diagnose und Therapie, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
JPH11514329A (ja) * 1994-02-18 1999-12-07 マリンクロット・メディカル・インコーポレイテッド 標識化ペプチド化合物
FR2720066B1 (fr) * 1994-05-20 1996-06-28 Rhone Poulenc Rorer Sa Peptides antagonistes de la neurotensine.
FR2722193B1 (fr) * 1994-07-08 1996-10-04 Sanofi Sa Derives n-oxydes de 1-(7-chloro-4-quinoleinyl)pyrazole-3-carboxamides substitues, procede pour leur preparation et les compositions pharmaceitiques les contenant
WO1996023527A1 (en) * 1995-02-03 1996-08-08 Mallinckrodt Medical, Inc. Method for the detection and localization of malignant human tumours

Also Published As

Publication number Publication date
CA2279530C (en) 2009-04-28
AU728712B2 (en) 2001-01-18
EP0968001B1 (en) 2003-11-05
HUP0001316A3 (en) 2001-10-29
WO1998033531A1 (en) 1998-08-06
HUP0001316A2 (hu) 2000-09-28
US6312661B1 (en) 2001-11-06
AU728712C (en) 2001-07-19
NO993846L (no) 1999-09-09
AU6262298A (en) 1998-08-25
US20020155064A1 (en) 2002-10-24
EP0968001A1 (en) 2000-01-05
NO993846D0 (no) 1999-08-10
JP2001511152A (ja) 2001-08-07
DE69819478D1 (de) 2003-12-11
CA2279530A1 (en) 1998-08-06
ATE253381T1 (de) 2003-11-15
DE69819478T2 (de) 2004-09-02

Similar Documents

Publication Publication Date Title
IL131386A0 (en) Method for the detection and localization of malignant human tumours
Raderer et al. Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo.
Mitran et al. Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist 177Lu‐DOTAGA‐PEG2‐RM26
US11547767B2 (en) 99mTc-EDDA/HYNIC-iPSMA as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen
Tjuvajev et al. Iododeoxyuridine uptake and retention as a measure of tumor growth
US20130330274A1 (en) Compositions and methods for detecting and treating cancer
EP3766893A1 (en) 177lu-dota-hynic-ipsma as a therapeutic radiopharmaceutical targeting prostate-specific membrane antigen
US20110117012A1 (en) Radiolabeled gallium complexes, methods for synthesis and use for pet imaging of egfr expression in malignant tumors
Bonnet‐Duquennoy et al. Targeted radionuclide therapy of melanoma: anti‐tumoural efficacy studies of a new 131I labelled potential agent
Liu et al. 99mTc-labeled SWL specific peptide for targeting EphA2 receptor
N Eberle et al. Synthetic peptide drugs for targeting skin cancer: malignant melanoma and melanotic lesions
NZ511280A (en) Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
O'Byrne et al. Scintigraphic imaging of small-cell lung cancer with [111In] pentetreotide, a radiolabelled somatostatin analogue
Nagy et al. Targeted cytotoxic somatostatin analogs: a modern approach to the therapy of various cancers
US9180214B1 (en) Gonadotropin-releasing hormone receptor-targeting peptides and their use to treat and diagnose cancer
Guo et al. A novel indium-111-labeled gonadotropin-releasing hormone peptide for human prostate cancer imaging
Yang et al. Evaluation of systemically administered radiolabeled epidermal growth factor as a brain tumor targeting agent
Miao et al. Therapeutic efficacy of a 177Lu-labeled DOTA conjugated α-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model
Merlo et al. Biodistribution of 111In‐labelled SCN‐bz‐DTPA‐BC‐2 MAb following loco‐regional injection into glioblastomas
Wygoda et al. Use of monoclonal anti-EGFR antibody in the radioimmunotherapy of malignant gliomas in the context of EGFR expression in grade III and IV tumors
JP2022517662A (ja) 腫瘍細胞外マトリックスにおける腫瘍性タンパク質に特異的なペプチドｐｅｔ／ｓｐｅｃｔプローブ
Nock et al. Theranostic perspectives in prostate cancer with the GRPR-antagonist NeoBOMB1–preclinical and first clinical results
Liu et al. In vivo imaging of human colorectal cancer using radiolabeled analogs of the uroguanylin peptide hormone
Raderer et al. Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results.
Arista et al. Intralesional administration of I-131 labelled monoclonal antibodies in the treatment of malignant gliomas